Dr. Erika Hamilton spoke with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

When I later calculated the financial impact of survivorship, the numbers were staggering: more than $1 million in lost ...

HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Dave Coulier sat down for an interview with CURE to discuss his recent tongue cancer diagnosis and his treatment journey.

Let Go and Let God. I ask God to give me and my wife strength, peace and serenity to go through this journey, especially at ...

There are two trials that I think are probably the most excited about. One of them is called the PEAK trial, and it was a ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

Ceremony completes my trio of words. This past year, I've become a vessel for ritual moments that transform ordinary spaces ...

She recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration, held in partnership with Blood ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...